Glucose tolerance and beta-cell function in islet autoantibody-positive children recruited to a secondary prevention study
Aims Children with type 1 diabetes (T1D) risk and islet autoantibodies are recruited to a secondary prevention study. The aims were to determine metabolic control in relation to human leukocyte antigen (HLA) genetic risk and islet autoantibodies in prepubertal children. Methods In 47 healthy childre...
Uloženo v:
| Vydáno v: | Pediatric diabetes Ročník 14; číslo 5; s. 341 - 349 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Former Munksgaard
John Wiley & Sons A/S
01.08.2013
|
| Témata: | |
| ISSN: | 1399-543X, 1399-5448, 1399-5448 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Aims
Children with type 1 diabetes (T1D) risk and islet autoantibodies are recruited to a secondary prevention study. The aims were to determine metabolic control in relation to human leukocyte antigen (HLA) genetic risk and islet autoantibodies in prepubertal children.
Methods
In 47 healthy children with GADA and at least one additional islet autoantibody, intravenous glucose tolerance test (IvGTT) and oral glucose tolerance test (OGTT) were performed 8–65 d apart. Hemoglobin A1c, plasma glucose as well as serum insulin and C‐peptide were determined at fasting and during IvGTT and OGTT.
Results
All children aged median 5.1 (4.0–9.2) yr had autoantibodies to two to six of the beta‐cell antigens GAD65, insulin, IA‐2, and the three amino acid position 325 variants of the ZnT8 transporter. In total, 20/47 children showed impaired glucose metabolism. Decreased (≤30 μU/mL insulin) first‐phase insulin response (FPIR) was found in 14/20 children while 11/20 had impaired glucose tolerance in the OGTT. Five children had both impaired glucose tolerance and FPIR ≤30 μU/mL insulin. Number and levels of autoantibodies were not associated with glucose metabolism, except for an increased frequency (p = 0.03) and level (p = 0.01) of ZnT8QA in children with impaired glucose metabolism. Among the children with impaired glucose metabolism, 13/20 had HLA‐DQ2/8, compared to 9/27 of the children with normal glucose metabolism (p = 0.03).
Conclusion
Secondary prevention studies in children with islet autoantibodies are complicated by variability in baseline glucose metabolism. Evaluation of metabolic control with both IvGTT and OGTT is critical and should be taken into account before randomization. All currently available autoantibody tests should be analyzed, including ZnT8QA. |
|---|---|
| AbstractList | Children with type 1 diabetes (T1D) risk and islet autoantibodies are recruited to a secondary prevention study. The aims were to determine metabolic control in relation to human leukocyte antigen (HLA) genetic risk and islet autoantibodies in prepubertal children.
In 47 healthy children with GADA and at least one additional islet autoantibody, intravenous glucose tolerance test (IvGTT) and oral glucose tolerance test (OGTT) were performed 8-65 d apart. Hemoglobin A1c, plasma glucose as well as serum insulin and C-peptide were determined at fasting and during IvGTT and OGTT.
All children aged median 5.1 (4.0-9.2) yr had autoantibodies to two to six of the beta-cell antigens GAD65, insulin, IA-2, and the three amino acid position 325 variants of the ZnT8 transporter. In total, 20/47 children showed impaired glucose metabolism. Decreased (≤ 30 μU/mL insulin) first-phase insulin response (FPIR) was found in 14/20 children while 11/20 had impaired glucose tolerance in the OGTT. Five children had both impaired glucose tolerance and FPIR ≤ 30 μU/mL insulin. Number and levels of autoantibodies were not associated with glucose metabolism, except for an increased frequency (p = 0.03) and level (p = 0.01) of ZnT8QA in children with impaired glucose metabolism. Among the children with impaired glucose metabolism, 13/20 had HLA-DQ2/8, compared to 9/27 of the children with normal glucose metabolism (p = 0.03).
Secondary prevention studies in children with islet autoantibodies are complicated by variability in baseline glucose metabolism. Evaluation of metabolic control with both IvGTT and OGTT is critical and should be taken into account before randomization. All currently available autoantibody tests should be analyzed, including ZnT8QA. Children with type 1 diabetes (T1D) risk and islet autoantibodies are recruited to a secondary prevention study. The aims were to determine metabolic control in relation to human leukocyte antigen (HLA) genetic risk and islet autoantibodies in prepubertal children. In 47 healthy children with GADA and at least one additional islet autoantibody, intravenous glucose tolerance test (IvGTT) and oral glucose tolerance test (OGTT) were performed 8-65 d apart. Hemoglobin A1c, plasma glucose as well as serum insulin and C-peptide were determined at fasting and during IvGTT and OGTT. All children aged median 5.1 (4.0-9.2) yr had autoantibodies to two to six of the beta-cell antigens GAD65, insulin, IA-2, and the three amino acid position 325 variants of the ZnT8 transporter. In total, 20/47 children showed impaired glucose metabolism. Decreased ( less than or equal to 30 mu U/mL insulin) first-phase insulin response (FPIR) was found in 14/20 children while 11/20 had impaired glucose tolerance in the OGTT. Five children had both impaired glucose tolerance and FPIR less than or equal to 30 mu U/mL insulin. Number and levels of autoantibodies were not associated with glucose metabolism, except for an increased frequency (p = 0.03) and level (p = 0.01) of ZnT8QA in children with impaired glucose metabolism. Among the children with impaired glucose metabolism, 13/20 had HLA-DQ2/8, compared to 9/27 of the children with normal glucose metabolism (p = 0.03). Secondary prevention studies in children with islet autoantibodies are complicated by variability in baseline glucose metabolism. Evaluation of metabolic control with both IvGTT and OGTT is critical and should be taken into account before randomization. All currently available autoantibody tests should be analyzed, including ZnT8QA. Aims Children with type 1 diabetes (T1D) risk and islet autoantibodies are recruited to a secondary prevention study. The aims were to determine metabolic control in relation to human leukocyte antigen (HLA) genetic risk and islet autoantibodies in prepubertal children. Methods In 47 healthy children with GADA and at least one additional islet autoantibody, intravenous glucose tolerance test (IvGTT) and oral glucose tolerance test (OGTT) were performed 8–65 d apart. Hemoglobin A1c, plasma glucose as well as serum insulin and C‐peptide were determined at fasting and during IvGTT and OGTT. Results All children aged median 5.1 (4.0–9.2) yr had autoantibodies to two to six of the beta‐cell antigens GAD65, insulin, IA‐2, and the three amino acid position 325 variants of the ZnT8 transporter. In total, 20/47 children showed impaired glucose metabolism. Decreased (≤30 μU/mL insulin) first‐phase insulin response (FPIR) was found in 14/20 children while 11/20 had impaired glucose tolerance in the OGTT. Five children had both impaired glucose tolerance and FPIR ≤30 μU/mL insulin. Number and levels of autoantibodies were not associated with glucose metabolism, except for an increased frequency (p = 0.03) and level (p = 0.01) of ZnT8QA in children with impaired glucose metabolism. Among the children with impaired glucose metabolism, 13/20 had HLA‐DQ2/8, compared to 9/27 of the children with normal glucose metabolism (p = 0.03). Conclusion Secondary prevention studies in children with islet autoantibodies are complicated by variability in baseline glucose metabolism. Evaluation of metabolic control with both IvGTT and OGTT is critical and should be taken into account before randomization. All currently available autoantibody tests should be analyzed, including ZnT8QA. AIMS: Children with type 1 diabetes (T1D) risk and islet autoantibodies are recruited to a secondary prevention study. The aims were to determine metabolic control in relation to human leukocyte antigen (HLA) genetic risk and islet autoantibodies in prepubertal children. METHODS: In 47 healthy children with GADA and at least one additional islet autoantibody, intravenous glucose tolerance test (IvGTT) and oral glucose tolerance test (OGTT) were performed 8-65 d apart. Hemoglobin A1c, plasma glucose as well as serum insulin and C-peptide were determined at fasting and during IvGTT and OGTT. RESULTS: All children aged median 5.1 (4.0-9.2) yr had autoantibodies to two to six of the beta-cell antigens GAD65, insulin, IA-2, and the three amino acid position 325 variants of the ZnT8 transporter. In total, 20/47 children showed impaired glucose metabolism. Decreased (≤30 μU/mL insulin) first-phase insulin response (FPIR) was found in 14/20 children while 11/20 had impaired glucose tolerance in the OGTT. Five children had both impaired glucose tolerance and FPIR ≤30 μU/mL insulin. Number and levels of autoantibodies were not associated with glucose metabolism, except for an increased frequency (p = 0.03) and level (p = 0.01) of ZnT8QA in children with impaired glucose metabolism. Among the children with impaired glucose metabolism, 13/20 had HLA-DQ2/8, compared to 9/27 of the children with normal glucose metabolism (p = 0.03). CONCLUSION: Secondary prevention studies in children with islet autoantibodies are complicated by variability in baseline glucose metabolism. Evaluation of metabolic control with both IvGTT and OGTT is critical and should be taken into account before randomization. All currently available autoantibody tests should be analyzed, including ZnT8QA. AIMS: Children with type 1 diabetes (T1D) risk and islet autoantibodies are recruited to a secondary prevention study. The aims were to determine metabolic control in relation to human leukocyte antigen (HLA) genetic risk and islet autoantibodies in prepubertal children. METHODS: In 47 healthy children with GADA and at least one additional islet autoantibody, intravenous glucose tolerance test (IvGTT) and oral glucose tolerance test (OGTT) were performed 8-65 d apart. Hemoglobin A1c, plasma glucose as well as serum insulin and C-peptide were determined at fasting and during IvGTT and OGTT. RESULTS: All children aged median 5.1 (4.0-9.2) yr had autoantibodies to two to six of the beta-cell antigens GAD65, insulin, IA-2, and the three amino acid position 325 variants of the ZnT8 transporter. In total, 20/47 children showed impaired glucose metabolism. Decreased (≤ 30 μU/mL insulin) first-phase insulin response (FPIR) was found in 14/20 children while 11/20 had impaired glucose tolerance in the OGTT. Five children had both impaired glucose tolerance and FPIR ≤ 30 μU/mL insulin. Number and levels of autoantibodies were not associated with glucose metabolism, except for an increased frequency (p = 0.03) and level (p = 0.01) of ZnT8QA in children with impaired glucose metabolism. Among the children with impaired glucose metabolism, 13/20 had HLA-DQ2/8, compared to 9/27 of the children with normal glucose metabolism (p = 0.03). CONCLUSION: Secondary prevention studies in children with islet autoantibodies are complicated by variability in baseline glucose metabolism. Evaluation of metabolic control with both IvGTT and OGTT is critical and should be taken into account before randomization. All currently available autoantibody tests should be analyzed, including ZnT8QA. Children with type 1 diabetes (T1D) risk and islet autoantibodies are recruited to a secondary prevention study. The aims were to determine metabolic control in relation to human leukocyte antigen (HLA) genetic risk and islet autoantibodies in prepubertal children.AIMSChildren with type 1 diabetes (T1D) risk and islet autoantibodies are recruited to a secondary prevention study. The aims were to determine metabolic control in relation to human leukocyte antigen (HLA) genetic risk and islet autoantibodies in prepubertal children.In 47 healthy children with GADA and at least one additional islet autoantibody, intravenous glucose tolerance test (IvGTT) and oral glucose tolerance test (OGTT) were performed 8-65 d apart. Hemoglobin A1c, plasma glucose as well as serum insulin and C-peptide were determined at fasting and during IvGTT and OGTT.METHODSIn 47 healthy children with GADA and at least one additional islet autoantibody, intravenous glucose tolerance test (IvGTT) and oral glucose tolerance test (OGTT) were performed 8-65 d apart. Hemoglobin A1c, plasma glucose as well as serum insulin and C-peptide were determined at fasting and during IvGTT and OGTT.All children aged median 5.1 (4.0-9.2) yr had autoantibodies to two to six of the beta-cell antigens GAD65, insulin, IA-2, and the three amino acid position 325 variants of the ZnT8 transporter. In total, 20/47 children showed impaired glucose metabolism. Decreased (≤ 30 μU/mL insulin) first-phase insulin response (FPIR) was found in 14/20 children while 11/20 had impaired glucose tolerance in the OGTT. Five children had both impaired glucose tolerance and FPIR ≤ 30 μU/mL insulin. Number and levels of autoantibodies were not associated with glucose metabolism, except for an increased frequency (p = 0.03) and level (p = 0.01) of ZnT8QA in children with impaired glucose metabolism. Among the children with impaired glucose metabolism, 13/20 had HLA-DQ2/8, compared to 9/27 of the children with normal glucose metabolism (p = 0.03).RESULTSAll children aged median 5.1 (4.0-9.2) yr had autoantibodies to two to six of the beta-cell antigens GAD65, insulin, IA-2, and the three amino acid position 325 variants of the ZnT8 transporter. In total, 20/47 children showed impaired glucose metabolism. Decreased (≤ 30 μU/mL insulin) first-phase insulin response (FPIR) was found in 14/20 children while 11/20 had impaired glucose tolerance in the OGTT. Five children had both impaired glucose tolerance and FPIR ≤ 30 μU/mL insulin. Number and levels of autoantibodies were not associated with glucose metabolism, except for an increased frequency (p = 0.03) and level (p = 0.01) of ZnT8QA in children with impaired glucose metabolism. Among the children with impaired glucose metabolism, 13/20 had HLA-DQ2/8, compared to 9/27 of the children with normal glucose metabolism (p = 0.03).Secondary prevention studies in children with islet autoantibodies are complicated by variability in baseline glucose metabolism. Evaluation of metabolic control with both IvGTT and OGTT is critical and should be taken into account before randomization. All currently available autoantibody tests should be analyzed, including ZnT8QA.CONCLUSIONSecondary prevention studies in children with islet autoantibodies are complicated by variability in baseline glucose metabolism. Evaluation of metabolic control with both IvGTT and OGTT is critical and should be taken into account before randomization. All currently available autoantibody tests should be analyzed, including ZnT8QA. |
| Author | Cilio, Corrado Jonsdottir, Berglind Jönsson, Björn Andersson, Cecilia Cedervall, Elisabeth Elding Larsson, Helena Carlsson, Annelie Ivarsson, Sten-Anders Neiderud, Jan Lernmark, Åke Larsson, Karin |
| Author_xml | – sequence: 1 givenname: Cecilia surname: Andersson fullname: Andersson, Cecilia email: Cecilia_K.Andersson@med.lu.se organization: Department of Clinical Sciences, Lund University/CRC, Skåne University Hospital SUS, Malmö, Sweden – sequence: 2 givenname: Annelie surname: Carlsson fullname: Carlsson, Annelie organization: Department of Paediatrics, Lund University, Skåne University Hospital SUS, Lund, Sweden – sequence: 3 givenname: Corrado surname: Cilio fullname: Cilio, Corrado organization: Department of Clinical Sciences, Lund University/CRC, Skåne University Hospital SUS, Malmö, Sweden – sequence: 4 givenname: Elisabeth surname: Cedervall fullname: Cedervall, Elisabeth organization: Department of Paediatrics, Helsingborg Hospital, Helsingborg, Sweden – sequence: 5 givenname: Sten-Anders surname: Ivarsson fullname: Ivarsson, Sten-Anders organization: Department of Clinical Sciences, Lund University/CRC, Skåne University Hospital SUS, Malmö, Sweden – sequence: 6 givenname: Berglind surname: Jonsdottir fullname: Jonsdottir, Berglind organization: Department of Clinical Sciences, Lund University/CRC, Skåne University Hospital SUS, Malmö, Sweden – sequence: 7 givenname: Björn surname: Jönsson fullname: Jönsson, Björn organization: Department of Paediatrics, Ystad Hospital, Ystad, Sweden – sequence: 8 givenname: Karin surname: Larsson fullname: Larsson, Karin organization: Department of Paediatrics, Kristianstad Hospital, Kristianstad, Sweden – sequence: 9 givenname: Jan surname: Neiderud fullname: Neiderud, Jan organization: Department of Paediatrics, Helsingborg Hospital, Helsingborg, Sweden – sequence: 10 givenname: Åke surname: Lernmark fullname: Lernmark, Åke organization: Department of Clinical Sciences, Lund University/CRC, Skåne University Hospital SUS, Malmö, Sweden – sequence: 11 givenname: Helena surname: Elding Larsson fullname: Elding Larsson, Helena organization: Department of Clinical Sciences, Lund University/CRC, Skåne University Hospital SUS, Malmö, Sweden |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23469940$$D View this record in MEDLINE/PubMed https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-223013$$DView record from Swedish Publication Index (Uppsala universitet) |
| BookMark | eNqNkk1v1DAQhiNURD_gwg9AOXIgxV9JnGPplm1RBagqhdvIsWepIRun_mhZfj3e3bI3JCxLHmmed2Y0fg-LvdGNWBQvKTmm-byd0NhjygjjT4oDyruuqoWQe7uYf9svDkP4QQhtOy6eFfuMi6brBDkofs-HpF3AMroBvRo1lmo0ZY9RVRqHoVykUUfrxtLmGwaMpUrRqTHa3plVNblgo73HUt_awXgcS4_aJxvR5JKlKgNqNxrlV-Xk8R7HTa0Qk1k9L54u1BDwxeN7VHx5f3Z9el5dfppfnJ5cVlbUlFcdk1p1sml7hkwgVUZr1tcSO17TRilpDGlZq7GjNc05LcVCNnSRWSWIaPhRobZ1wwNOqYfJ22WeB5yyMDkf1QAeAyqvb2FIEBAyNVit1qMGqEm9YEw0oI3SIFjdQt9qAzU32LaK562ue7z5Z4-ZvTkB579DSsAYJ5Rn_PUWn7y7SxgiLG1Yr1uN6FIAKjiRDevk_6C0IYJLKjP66hFN_RLNboi_v50BugUe7ICrXZ4SWPsI1j6CjY_g89nsYhNlTbXV2BDx106j_E9oWt7W8PXjHD5cz87FzdU7uOJ_AGCZz2w |
| ContentType | Journal Article |
| Contributor | Shalouie, Aliram Andersson, Cecilia Larsson, Helena E Edgren, Joakim Brundin, Charlotte Carlsson, Annelie Neiderud, Jan Nilsson, Caroline Ivarsson, Sten Larsson, Karin Hemmendal, Jennifer Cilio, Corrado Jonsdottir, Berglind Winqvist, Annika Arvastsson, Jeanette Persson, Lars Åke Gard, Thomas Mestan, Zeliha Nilsson, Anita Lindberg, Bengt Örtqvist, Eva Jönsson, Ida Olsson, Ann Jönsson, Björn Cederwall, Elisabeth Meineche, Susanne Bach Hansson, Gertie Wigheden, Ingrid Lernmark, Åke |
| Contributor_xml | – sequence: 1 givenname: Helena E surname: Larsson fullname: Larsson, Helena E – sequence: 2 givenname: Åke surname: Lernmark fullname: Lernmark, Åke – sequence: 3 givenname: Caroline surname: Nilsson fullname: Nilsson, Caroline – sequence: 4 givenname: Gertie surname: Hansson fullname: Hansson, Gertie – sequence: 5 givenname: Jeanette surname: Arvastsson fullname: Arvastsson, Jeanette – sequence: 6 givenname: Charlotte surname: Brundin fullname: Brundin, Charlotte – sequence: 7 givenname: Jennifer surname: Hemmendal fullname: Hemmendal, Jennifer – sequence: 8 givenname: Ida surname: Jönsson fullname: Jönsson, Ida – sequence: 9 givenname: Anita surname: Nilsson fullname: Nilsson, Anita – sequence: 10 givenname: Zeliha surname: Mestan fullname: Mestan, Zeliha – sequence: 11 givenname: Aliram surname: Shalouie fullname: Shalouie, Aliram – sequence: 12 givenname: Ingrid surname: Wigheden fullname: Wigheden, Ingrid – sequence: 13 givenname: Annika surname: Winqvist fullname: Winqvist, Annika – sequence: 14 givenname: Cecilia surname: Andersson fullname: Andersson, Cecilia – sequence: 15 givenname: Susanne Bach surname: Meineche fullname: Meineche, Susanne Bach – sequence: 16 givenname: Annelie surname: Carlsson fullname: Carlsson, Annelie – sequence: 17 givenname: Elisabeth surname: Cederwall fullname: Cederwall, Elisabeth – sequence: 18 givenname: Corrado surname: Cilio fullname: Cilio, Corrado – sequence: 19 givenname: Joakim surname: Edgren fullname: Edgren, Joakim – sequence: 20 givenname: Sten surname: Ivarsson fullname: Ivarsson, Sten – sequence: 21 givenname: Berglind surname: Jonsdottir fullname: Jonsdottir, Berglind – sequence: 22 givenname: Björn surname: Jönsson fullname: Jönsson, Björn – sequence: 23 givenname: Karin surname: Larsson fullname: Larsson, Karin – sequence: 24 givenname: Bengt surname: Lindberg fullname: Lindberg, Bengt – sequence: 25 givenname: Jan surname: Neiderud fullname: Neiderud, Jan – sequence: 26 givenname: Ann surname: Olsson fullname: Olsson, Ann – sequence: 27 givenname: Lars Åke surname: Persson fullname: Persson, Lars Åke – sequence: 28 givenname: Eva surname: Örtqvist fullname: Örtqvist, Eva – sequence: 29 givenname: Thomas surname: Gard fullname: Gard, Thomas |
| Copyright | 2013 John Wiley & Sons A/S 2013 John Wiley & Sons A/S. |
| Copyright_xml | – notice: 2013 John Wiley & Sons A/S – notice: 2013 John Wiley & Sons A/S. |
| CorporateAuthor | DiAPREV-IT Study Group Section V Department of Clinical Sciences, Lund Clinical Sciences, Helsingborg Strategiska forskningsområden (SFO) Medicinska fakulteten Paediatric Endocrinology Pediatrik, Lund Institutionen för kliniska vetenskaper, Lund Sektion II Kliniska Vetenskaper, Helsingborg Lunds universitet Section II Profile areas and other strong research environments Department of Clinical Sciences, Malmö Lund University Sektion V Diabetes - Immunovirology Celiac Disease and Diabetes Unit Diabetes - immunovirologi EpiHealth: Epidemiology for Health EXODIAB: Excellence of Diabetes Research in Sweden Faculty of Medicine Celiaki och diabetes Strategic research areas (SRA) Paediatrics (Lund) Pediatrisk endokrinologi Profilområden och andra starka forskningsmiljöer Institutionen för kliniska vetenskaper, Malmö |
| CorporateAuthor_xml | – name: DiAPREV-IT Study Group – name: Strategiska forskningsområden (SFO) – name: Section II – name: Diabetes - Immunovirology – name: Diabetes - immunovirologi – name: Celiac Disease and Diabetes Unit – name: EpiHealth: Epidemiology for Health – name: Strategic research areas (SRA) – name: Clinical Sciences, Helsingborg – name: Department of Clinical Sciences, Lund – name: Paediatric Endocrinology – name: Lund University – name: EXODIAB: Excellence of Diabetes Research in Sweden – name: Sektion V – name: Section V – name: Profile areas and other strong research environments – name: Department of Clinical Sciences, Malmö – name: Faculty of Medicine – name: Medicinska fakulteten – name: Sektion II – name: Kliniska Vetenskaper, Helsingborg – name: Celiaki och diabetes – name: Institutionen för kliniska vetenskaper, Malmö – name: Institutionen för kliniska vetenskaper, Lund – name: Lunds universitet – name: Profilområden och andra starka forskningsmiljöer – name: Paediatrics (Lund) – name: Pediatrik, Lund – name: Pediatrisk endokrinologi |
| DBID | BSCLL CGR CUY CVF ECM EIF NPM 7X8 7T5 H94 ADTPV AOWAS DF2 D95 |
| DOI | 10.1111/pedi.12023 |
| DatabaseName | Istex Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Immunology Abstracts AIDS and Cancer Research Abstracts SwePub SwePub Articles SWEPUB Uppsala universitet SWEPUB Lunds universitet |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic AIDS and Cancer Research Abstracts Immunology Abstracts |
| DatabaseTitleList | MEDLINE AIDS and Cancer Research Abstracts MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1399-5448 |
| EndPage | 349 |
| ExternalDocumentID | oai_portal_research_lu_se_publications_505f2246_cdac_4257_b7cd_53de77a30016 oai_DiVA_org_uu_223013 23469940 PEDI12023 ark_67375_WNG_JTDH4VRB_R |
| Genre | article Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: UMAS Fund – fundername: the Knut and Alice Wallenberg Foundation – fundername: Swedish Childhood Diabetes Foundation – fundername: Swedish Diabetes Association – fundername: Swedish Research Council funderid: 14064 – fundername: the Skåne County Council for Research and Development – fundername: National Institutes of Health funderid: DK26190 – fundername: the Juvenile Diabetes Research Foundation funderid: 17‐2011‐576 – fundername: NIDDK NIH HHS grantid: DK26190 – fundername: NIDDK NIH HHS grantid: R01 DK026190 |
| GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 123 1OC 24P 29O 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5HH 5LA 5VS 66C 702 7PT 7RV 7X7 8-0 8-1 8-3 8-4 8-5 8C1 8FI 8FJ 8UM 930 A01 A03 AAESR AAEVG AAFWJ AAKAS AAMMB AANHP AAONW AASGY AAWTL AAXRX AAZKR ABCQN ABCUV ABEML ABJNI ABPPZ ABPVW ABUWG ABXGK ACAHQ ACBWZ ACCMX ACCZN ACGFS ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZCM ADZMN AEFGJ AEIMD AENEX AFBPY AFEBI AFGKR AFKRA AFZJQ AGQPQ AGXDD AIACR AIDQK AIDYY AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BENPR BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG CCPQU COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM EBS EJD EMOBN EX3 F00 F01 F04 F5P FEDTE FUBAC FYUFA G-S G.N GODZA H.X H13 HF~ HMCUK HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NAPCQ NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PHGZM PHGZT PIMPY PJZUB PPXIY Q.N Q11 QB0 R.K ROL RPM RX1 SUPJJ TEORI UB1 UKHRP W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WVDHM WXI XG1 YFH ZZTAW ~IA ~WT AAHHS AAJEY ACCFJ AEEZP AEQDE AEUQT AFPWT AIWBW AJBDE ESX RHX WRC CGR CUY CVF ECM EIF NPM 7X8 7T5 H94 ADTPV AFFHD AOWAS DF2 D95 |
| ID | FETCH-LOGICAL-i4513-928ca9867b2e24e1adcc2b58e93516aa8dd0727ce9151dccc84f861f24ea40463 |
| IEDL.DBID | DRFUL |
| ISICitedReferencesCount | 10 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000322989100004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1399-543X 1399-5448 |
| IngestDate | Tue Nov 04 16:04:45 EST 2025 Tue Nov 04 16:47:27 EST 2025 Fri Sep 05 08:06:55 EDT 2025 Sun Nov 09 11:17:32 EST 2025 Wed Feb 19 02:41:55 EST 2025 Wed Jan 22 16:57:47 EST 2025 Sun Sep 21 06:18:47 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | FPIR ZnT8 secondary prevention insulin autoantibodies T1D IA-2 autoantibodies HLA genotype diabetes mellitus zinc transporter glucose tolerance GAD65 autoantibodies |
| Language | English |
| License | 2013 John Wiley & Sons A/S. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-i4513-928ca9867b2e24e1adcc2b58e93516aa8dd0727ce9151dccc84f861f24ea40463 |
| Notes | Swedish Research Council - No. 14064 National Institutes of Health - No. DK26190 UMAS Fund ark:/67375/WNG-JTDH4VRB-R the Juvenile Diabetes Research Foundation - No. 17-2011-576 ArticleID:PEDI12023 the Skåne County Council for Research and Development istex:E5D81344B08CF0B3EDDEEE1A762B72DE03934E6B Swedish Childhood Diabetes Foundation Swedish Diabetes Association the Knut and Alice Wallenberg Foundation See Appendix. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
| PMID | 23469940 |
| PQID | 1416043818 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | swepub_primary_oai_portal_research_lu_se_publications_505f2246_cdac_4257_b7cd_53de77a30016 swepub_primary_oai_DiVA_org_uu_223013 proquest_miscellaneous_1430862983 proquest_miscellaneous_1416043818 pubmed_primary_23469940 wiley_primary_10_1111_pedi_12023_PEDI12023 istex_primary_ark_67375_WNG_JTDH4VRB_R |
| PublicationCentury | 2000 |
| PublicationDate | August 2013 |
| PublicationDateYYYYMMDD | 2013-08-01 |
| PublicationDate_xml | – month: 08 year: 2013 text: August 2013 |
| PublicationDecade | 2010 |
| PublicationPlace | Former Munksgaard |
| PublicationPlace_xml | – name: Former Munksgaard – name: Denmark |
| PublicationTitle | Pediatric diabetes |
| PublicationTitleAlternate | Pediatr Diabetes |
| PublicationYear | 2013 |
| Publisher | John Wiley & Sons A/S |
| Publisher_xml | – name: John Wiley & Sons A/S |
| References | Stene LC, Barriga K, Hoffman M et al. Normal but increasing hemoglobin A1c levels predict progression from islet autoimmunity to overt type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). Pediatr Diabetes 2006: 7: 247-253. Karvonen M, Pitkaniemi J, Tuomilehto J. The onset age of type 1 diabetes in Finnish children has become younger. The Finnish Childhood Diabetes Registry Group. Diabetes Care 1999: 22: 1066-1070. Karlberg J, Luo ZC, Albertsson-Wikland K. Body mass index reference values (mean and SD) for Swedish children. Acta Paediatr 2001: 90: 1427-1434. Ilonen J, Sjoroos M, Knip M et al. Estimation of genetic risk for type 1 diabetes. Am J Med Genet 2002: 115: 30-36. Bingley PJ, Christie MR, Bonifacio E et al. Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes 1994: 43: 1304-1310. Ranke MB. Diagnostics of Endocrine Function in Children and Adolescents3rd revised and extended edition. Basel: Karger, 2003: 321-327. Mrena S, Savola K, Kulmala P, Akerblom HK, Knip M. Natural course of preclinical type 1 diabetes in siblings of affected children. Acta Paediatr 2003: 92: 1403-1410. Siljander HT, Veijola R, Reunanen A, Virtanen SM, Akerblom HK, Knip M. Prediction of type 1 diabetes among siblings of affected children and in the general population. Diabetologia 2007: 50: 2272-2275. Schlosser M, Mueller PW, Torn C, Bonifacio E, Bingley PJ. Diabetes Antibody Standardization Program: evaluation of assays for insulin autoantibodies. Diabetologia 2010: 53: 2611-2620. Yu L, Boulware DC, Beam CA et al. Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies. Diabetes Care 2012: 35: 1213-1218. Barker JM, Barriga KJ, Yu L et al. Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J Clin Endocrinol Metab 2004: 89: 3896-3902. Nejentsev S, Sjoroos M, Soukka T et al. Population-based genetic screening for the estimation of type 1 diabetes mellitus risk in Finland: selective genotyping of markers in the HLA-DQB1, HLA-DQA1 and HLA-DRB1 loci. Diabet Med 1999: 16: 985-992. Pundziute-Lycka A, Dahlquist G, Urbonaite B, Zalinkevicius R. Time trend of childhood type 1 diabetes incidence in Lithuania and Sweden, 1983-2000. Acta Paediatr 2004: 93: 1519-1524. Orban T, Sosenko JM, Cuthbertson D et al. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2009: 32: 2269-2274. Lampasona V, Schlosser M, Mueller PW et al. Diabetes antibody standardization program: first proficiency evaluation of assays for autoantibodies to zinc transporter 8. Clin Chem 2011: 57: 1693-1702. Bingley PJ, Williams AJ, Gale EA. Optimized autoantibody-based risk assessment in family members. Implications for future intervention trials. Diabetes Care 1999: 22: 1796-1801. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001: 358: 221-229. Keskinen P, Korhonen S, Kupila A et al. First-phase insulin response in young healthy children at genetic and immunological risk for Type I diabetes. Diabetologia 2002: 45: 1639-1648. Andersson C, Vaziri-Sani F, Delli AJ et al; the BDD Study group. Triple-specificity of ZnT8 autoantibodies in relation to HLA and other islet autoantibodies in childhood and adolescent type 1 diabetes. Pediatr Diabetes [Epub 11 September 2012]. Bingley PJ, Mahon JL, Gale EA. Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT). Diabetes Care 2008: 31: 146-150. Harjutsalo V, Sjoberg L, Tuomilehto J. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 2008: 371: 1777-1782. Andersson C, Larsson K, Vaziri-Sani F et al. The three ZNT8 autoantibody variants together improve the diagnostic sensitivity of childhood and adolescent type 1 diabetes. Autoimmunity 2011: 44: 394-405. Xu P, Beam CA, Cuthbertson D, Sosenko JM, Skyler JS, Krischer JP. Prognostic accuracy of immunologic and metabolic markers for type 1 diabetes in a high-risk population: receiver operating characteristic analysis. Diabetes Care 2012: 35: 1975-1980. Kukko M, Kimpimaki T, Korhonen S et al. Dynamics of diabetes-associated autoantibodies in young children with human leukocyte antigen-conferred risk of type 1 diabetes recruited from the general population. J Clin Endocrinol Metab 2005: 90: 2712-2717. Lynch KF, Lernmark B, Merlo J, Cilio CM, Ivarsson SA, Lernmark A. Cord blood islet autoantibodies and seasonal association with the type 1 diabetes high-risk genotype. J Perinatol 2008: 28: 211-217. Redondo MJ, Babu S, Zeidler A et al. Specific human leukocyte antigen DQ influence on expression of antiislet autoantibodies and progression to type 1 diabetes. J Clin Endocrinol Metab 2006: 91: 1705-1713. Ziegler AG, Pflueger M, Winkler C et al. Accelerated progression from islet autoimmunity to diabetes is causing the escalating incidence of type 1 diabetes in young children. J Autoimmun 2011: 37: 3-7. Sosenko JM, Skyler JS, Herold KC, Palmer JP. The metabolic progression to type 1 diabetes as indicated by serial oral glucose tolerance testing in the Diabetes Prevention Trial-type 1. Diabetes 2012: 61: 1331-1337. Wenzlau JM, Juhl K, Yu L et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 2007: 104: 17040-17045. 2012; 61 2007; 104 2006; 91 2010; 53 2001; 90 2005; 90 2004; 89 2006; 7 1999; 22 2002; 115 2011; 57 2007; 50 2011; 37 2003 2008; 31 2012; 35 1994; 43 2009; 32 2004; 93 2003; 92 2002; 45 1999; 16 2008; 28 2011; 44 2008; 371 2001; 358 |
| References_xml | – reference: Yu L, Boulware DC, Beam CA et al. Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies. Diabetes Care 2012: 35: 1213-1218. – reference: Mrena S, Savola K, Kulmala P, Akerblom HK, Knip M. Natural course of preclinical type 1 diabetes in siblings of affected children. Acta Paediatr 2003: 92: 1403-1410. – reference: Ilonen J, Sjoroos M, Knip M et al. Estimation of genetic risk for type 1 diabetes. Am J Med Genet 2002: 115: 30-36. – reference: Karlberg J, Luo ZC, Albertsson-Wikland K. Body mass index reference values (mean and SD) for Swedish children. Acta Paediatr 2001: 90: 1427-1434. – reference: Bingley PJ, Williams AJ, Gale EA. Optimized autoantibody-based risk assessment in family members. Implications for future intervention trials. Diabetes Care 1999: 22: 1796-1801. – reference: Andersson C, Larsson K, Vaziri-Sani F et al. The three ZNT8 autoantibody variants together improve the diagnostic sensitivity of childhood and adolescent type 1 diabetes. Autoimmunity 2011: 44: 394-405. – reference: Bingley PJ, Christie MR, Bonifacio E et al. Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes 1994: 43: 1304-1310. – reference: Xu P, Beam CA, Cuthbertson D, Sosenko JM, Skyler JS, Krischer JP. Prognostic accuracy of immunologic and metabolic markers for type 1 diabetes in a high-risk population: receiver operating characteristic analysis. Diabetes Care 2012: 35: 1975-1980. – reference: Wenzlau JM, Juhl K, Yu L et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 2007: 104: 17040-17045. – reference: Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001: 358: 221-229. – reference: Keskinen P, Korhonen S, Kupila A et al. First-phase insulin response in young healthy children at genetic and immunological risk for Type I diabetes. Diabetologia 2002: 45: 1639-1648. – reference: Harjutsalo V, Sjoberg L, Tuomilehto J. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 2008: 371: 1777-1782. – reference: Orban T, Sosenko JM, Cuthbertson D et al. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2009: 32: 2269-2274. – reference: Nejentsev S, Sjoroos M, Soukka T et al. Population-based genetic screening for the estimation of type 1 diabetes mellitus risk in Finland: selective genotyping of markers in the HLA-DQB1, HLA-DQA1 and HLA-DRB1 loci. Diabet Med 1999: 16: 985-992. – reference: Kukko M, Kimpimaki T, Korhonen S et al. Dynamics of diabetes-associated autoantibodies in young children with human leukocyte antigen-conferred risk of type 1 diabetes recruited from the general population. J Clin Endocrinol Metab 2005: 90: 2712-2717. – reference: Sosenko JM, Skyler JS, Herold KC, Palmer JP. The metabolic progression to type 1 diabetes as indicated by serial oral glucose tolerance testing in the Diabetes Prevention Trial-type 1. Diabetes 2012: 61: 1331-1337. – reference: Siljander HT, Veijola R, Reunanen A, Virtanen SM, Akerblom HK, Knip M. Prediction of type 1 diabetes among siblings of affected children and in the general population. Diabetologia 2007: 50: 2272-2275. – reference: Lynch KF, Lernmark B, Merlo J, Cilio CM, Ivarsson SA, Lernmark A. Cord blood islet autoantibodies and seasonal association with the type 1 diabetes high-risk genotype. J Perinatol 2008: 28: 211-217. – reference: Redondo MJ, Babu S, Zeidler A et al. Specific human leukocyte antigen DQ influence on expression of antiislet autoantibodies and progression to type 1 diabetes. J Clin Endocrinol Metab 2006: 91: 1705-1713. – reference: Pundziute-Lycka A, Dahlquist G, Urbonaite B, Zalinkevicius R. Time trend of childhood type 1 diabetes incidence in Lithuania and Sweden, 1983-2000. Acta Paediatr 2004: 93: 1519-1524. – reference: Andersson C, Vaziri-Sani F, Delli AJ et al; the BDD Study group. Triple-specificity of ZnT8 autoantibodies in relation to HLA and other islet autoantibodies in childhood and adolescent type 1 diabetes. Pediatr Diabetes [Epub 11 September 2012]. – reference: Barker JM, Barriga KJ, Yu L et al. Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J Clin Endocrinol Metab 2004: 89: 3896-3902. – reference: Lampasona V, Schlosser M, Mueller PW et al. Diabetes antibody standardization program: first proficiency evaluation of assays for autoantibodies to zinc transporter 8. Clin Chem 2011: 57: 1693-1702. – reference: Ziegler AG, Pflueger M, Winkler C et al. Accelerated progression from islet autoimmunity to diabetes is causing the escalating incidence of type 1 diabetes in young children. J Autoimmun 2011: 37: 3-7. – reference: Bingley PJ, Mahon JL, Gale EA. Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT). Diabetes Care 2008: 31: 146-150. – reference: Ranke MB. Diagnostics of Endocrine Function in Children and Adolescents3rd revised and extended edition. Basel: Karger, 2003: 321-327. – reference: Karvonen M, Pitkaniemi J, Tuomilehto J. The onset age of type 1 diabetes in Finnish children has become younger. The Finnish Childhood Diabetes Registry Group. Diabetes Care 1999: 22: 1066-1070. – reference: Stene LC, Barriga K, Hoffman M et al. Normal but increasing hemoglobin A1c levels predict progression from islet autoimmunity to overt type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). Pediatr Diabetes 2006: 7: 247-253. – reference: Schlosser M, Mueller PW, Torn C, Bonifacio E, Bingley PJ. Diabetes Antibody Standardization Program: evaluation of assays for insulin autoantibodies. Diabetologia 2010: 53: 2611-2620. – article-title: Triple‐specificity of ZnT8 autoantibodies in relation to HLA and other islet autoantibodies in childhood and adolescent type 1 diabetes publication-title: Pediatr Diabetes – volume: 35 start-page: 1213 year: 2012 end-page: 1218 article-title: Zinc transporter‐8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies publication-title: Diabetes Care – volume: 358 start-page: 221 year: 2001 end-page: 229 article-title: Type 1 diabetes: new perspectives on disease pathogenesis and treatment publication-title: Lancet – volume: 93 start-page: 1519 year: 2004 end-page: 1524 article-title: Time trend of childhood type 1 diabetes incidence in Lithuania and Sweden, 1983–2000 publication-title: Acta Paediatr – volume: 44 start-page: 394 year: 2011 end-page: 405 article-title: The three ZNT8 autoantibody variants together improve the diagnostic sensitivity of childhood and adolescent type 1 diabetes publication-title: Autoimmunity – volume: 35 start-page: 1975 year: 2012 end-page: 1980 article-title: Prognostic accuracy of immunologic and metabolic markers for type 1 diabetes in a high‐risk population: receiver operating characteristic analysis publication-title: Diabetes Care – volume: 7 start-page: 247 year: 2006 end-page: 253 article-title: Normal but increasing hemoglobin A1c levels predict progression from islet autoimmunity to overt type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY) publication-title: Pediatr Diabetes – start-page: 321 year: 2003 end-page: 327 – volume: 89 start-page: 3896 year: 2004 end-page: 3902 article-title: Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY) publication-title: J Clin Endocrinol Metab – volume: 57 start-page: 1693 year: 2011 end-page: 1702 article-title: Diabetes antibody standardization program: first proficiency evaluation of assays for autoantibodies to zinc transporter 8 publication-title: Clin Chem – volume: 22 start-page: 1796 year: 1999 end-page: 1801 article-title: Optimized autoantibody‐based risk assessment in family members. Implications for future intervention trials publication-title: Diabetes Care – volume: 16 start-page: 985 year: 1999 end-page: 992 article-title: Population‐based genetic screening for the estimation of type 1 diabetes mellitus risk in Finland: selective genotyping of markers in the HLA‐DQB1, HLA‐DQA1 and HLA‐DRB1 loci publication-title: Diabet Med – volume: 22 start-page: 1066 year: 1999 end-page: 1070 article-title: The onset age of type 1 diabetes in Finnish children has become younger. The Finnish Childhood Diabetes Registry Group publication-title: Diabetes Care – volume: 32 start-page: 2269 year: 2009 end-page: 2274 article-title: Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial‐Type 1 publication-title: Diabetes Care – volume: 31 start-page: 146 year: 2008 end-page: 150 article-title: Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT) publication-title: Diabetes Care – volume: 92 start-page: 1403 year: 2003 end-page: 1410 article-title: Natural course of preclinical type 1 diabetes in siblings of affected children publication-title: Acta Paediatr – volume: 90 start-page: 2712 year: 2005 end-page: 2717 article-title: Dynamics of diabetes‐associated autoantibodies in young children with human leukocyte antigen‐conferred risk of type 1 diabetes recruited from the general population publication-title: J Clin Endocrinol Metab – volume: 37 start-page: 3 year: 2011 end-page: 7 article-title: Accelerated progression from islet autoimmunity to diabetes is causing the escalating incidence of type 1 diabetes in young children publication-title: J Autoimmun – volume: 90 start-page: 1427 year: 2001 end-page: 1434 article-title: Body mass index reference values (mean and SD) for Swedish children publication-title: Acta Paediatr – volume: 61 start-page: 1331 year: 2012 end-page: 1337 article-title: The metabolic progression to type 1 diabetes as indicated by serial oral glucose tolerance testing in the Diabetes Prevention Trial‐type 1 publication-title: Diabetes – volume: 45 start-page: 1639 year: 2002 end-page: 1648 article-title: First‐phase insulin response in young healthy children at genetic and immunological risk for Type I diabetes publication-title: Diabetologia – volume: 50 start-page: 2272 year: 2007 end-page: 2275 article-title: Prediction of type 1 diabetes among siblings of affected children and in the general population publication-title: Diabetologia – volume: 115 start-page: 30 year: 2002 end-page: 36 article-title: Estimation of genetic risk for type 1 diabetes publication-title: Am J Med Genet – volume: 28 start-page: 211 year: 2008 end-page: 217 article-title: Cord blood islet autoantibodies and seasonal association with the type 1 diabetes high‐risk genotype publication-title: J Perinatol – volume: 53 start-page: 2611 year: 2010 end-page: 2620 article-title: Diabetes Antibody Standardization Program: evaluation of assays for insulin autoantibodies publication-title: Diabetologia – volume: 104 start-page: 17040 year: 2007 end-page: 17045 article-title: The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes publication-title: Proc Natl Acad Sci U S A – volume: 371 start-page: 1777 year: 2008 end-page: 1782 article-title: Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study publication-title: Lancet – volume: 43 start-page: 1304 year: 1994 end-page: 1310 article-title: Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody‐positive relatives publication-title: Diabetes – volume: 91 start-page: 1705 year: 2006 end-page: 1713 article-title: Specific human leukocyte antigen DQ influence on expression of antiislet autoantibodies and progression to type 1 diabetes publication-title: J Clin Endocrinol Metab |
| SSID | ssj0017934 |
| Score | 2.0589507 |
| Snippet | Aims
Children with type 1 diabetes (T1D) risk and islet autoantibodies are recruited to a secondary prevention study. The aims were to determine metabolic... Children with type 1 diabetes (T1D) risk and islet autoantibodies are recruited to a secondary prevention study. The aims were to determine metabolic control... AIMS: Children with type 1 diabetes (T1D) risk and islet autoantibodies are recruited to a secondary prevention study. The aims were to determine metabolic... |
| SourceID | swepub proquest pubmed wiley istex |
| SourceType | Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 341 |
| SubjectTerms | Autoantibodies - blood Cation Transport Proteins - genetics Cation Transport Proteins - immunology Child Child, Preschool Clinical Medicine diabetes mellitus Diabetes Mellitus, Type 1 - immunology Diabetes Mellitus, Type 1 - prevention & control Endocrinology and Diabetes Endokrinologi och diabetes Female FPIR GAD65 autoantibodies Glucose - metabolism Glucose Intolerance - immunology glucose tolerance Glucose Tolerance Test Glutamate Decarboxylase - immunology HLA Antigens - immunology HLA genotype HLA-DQ Antigens - immunology Humans IA-2 autoantibodies Insulin - immunology insulin autoantibodies Insulin-Secreting Cells - immunology Klinisk medicin Male Medical and Health Sciences Medicin och hälsovetenskap Pediatrics Pediatrik Receptor-Like Protein Tyrosine Phosphatases, Class 8 - immunology secondary prevention T1D zinc transporter Zinc Transporter 8 ZnT8 |
| Title | Glucose tolerance and beta-cell function in islet autoantibody-positive children recruited to a secondary prevention study |
| URI | https://api.istex.fr/ark:/67375/WNG-JTDH4VRB-R/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fpedi.12023 https://www.ncbi.nlm.nih.gov/pubmed/23469940 https://www.proquest.com/docview/1416043818 https://www.proquest.com/docview/1430862983 https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-223013 |
| Volume | 14 |
| WOSCitedRecordID | wos000322989100004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1399-5448 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017934 issn: 1399-5448 databaseCode: DRFUL dateStart: 20000101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3da9RAEB_aq4gvfn_Ej7KC-iBELt-74Ev1eq1Sj3K05-HLsrvZ2NByOS5J0RfxT_Bv9C9xJsnFCkUQIQ-BnWzCzszubzazvwF4xlVsImPQeBGNuqHHhy6GEdzNIq2E1ZnOGuL52UEymfD5XBxuwOv1WZiWH6LfcCPPaOZrcnClywtOvsTJ_ZVH1b83YctHw40GsDWajo8P-r8IaHttUVsh3CgM5h09KWXy_H4aUSkN6JfLIGbPH_ondG3WnvGN__vqm3C9w5xspzWSW7BhF7fh6ofur_od-LbX5q2zqjizVGjDMrVImbaV-vn9B23tM1r-SIUsx6tEXTNVVwVqJddF-hWl2uSvc8vWp8MZTqWrmgAtdssUKynyTvHD2bJjjcLeGnLbu3A83j16u-92dRncPIy8wBU-N0rwONG-9UPrqdQYX0fciiDyYqV4mg4RFhkrEE5gm-FhxmMvQ1kVEkPZPRgsioV9AEwJnWUqwzicoAUujUr7Q2sCjPqiRAXKgReNcuSy5d6QanVKqWhJJD9O9uT7o9F-OJu-kVMHnq61J9FBaGjUwhZ1ibGNFzdEZvxvMgGFdoIHDtxvVd-_0Q_CWIhw6MDz1hb6FmLmHuWzHVmsPsu6loi0EFA78OkSuTaYkh2D04k8q2Vp5fLC1qxELJoRvZ80qTKS5lKpE5PKKEhtgoNB6NyBl4119X2vYziyK9nYlTzcHb1r7h7-i_AjuOY3lT4ot_ExDKpVbZ_AFXNe5eVqGzaTOd_u_OsXQ6st-w |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3bbtNAEF1Bi4AX7hdzXSTgAckovu8-FtI0hTSqojSNeBmt12uwqOwotit4QXwC38iXMGM7pkgVEkLKQyRPNtbOmd0z6_EZxp4LFepAawQvslHbd8TAxjRC2GkQK2niNE4b4fnFJJpOxXIpD7vaHHoXptWH6A_cKDKa9ZoCnA6kz0T5Clf31w61_77Itn3EEQJ8ezgbHU36xwgIvrarrZR24HvLTp-USnl-_xppKc3ol_M4Zi8g-id3bTaf0fX_vO0b7FrHOvlOC5Ob7ILJb7HLB91z9dvs215buc6r4sRQqw3DVZ7w2FTq5_cfdLjPaQMkJ_IMPyV6m6u6KtAvWVwkX9GqLf86NXzzfjjHxXRdE6XFYbniJeXeCd45X3W6UThaI297hx2Ndudvx3bXmcHO_MDxbOkKraQIo9g1rm8clWjtxoEw0gucUCmRJAMkRtpIJBR4TQs_FaGToq3ySaPsLtvKi9zcZ1zJOE1Vipk4kQvcHFXsDoz2MO8LIuUpi71svAOrVn0D1PozFaNFARxP9-DdfDj2F7M3MLPYs437AEOEpkblpqhLzG6csJEyE3-z8Si5k8Kz2L3W9_0_up4fSukPLPaiBUN_hbS5h9liB4r1R6hrQK6FlNpiH86xa9Mp6DScPsFJDaWB1ZnDWUA2mpLAH-hEaaDVFOJIJxB4iYlwMoifW-xVA69-7E0WR7iCBldwuDvcb749-Bfjp-zKeH4wgcn-9P1DdtVt-n5QpeMjtlWta_OYXdKnVVaun3Rh9gsXmzED |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEB5BiiouvKHmuUjAAckofu8eC2naQoiiqA0Rl9F6vaYRVRwlcQUXxE_gN_JLmLEdU6QKCSH5YGnHa2tnZveb9ew3AM-kjk1kDBkvoVE39GTXpTBCunmUamXTPM0r4vnJIBkO5XSqRk1uDp-Fqfkh2g039oxqvmYHt4ssP-flC5rdX3lc_vsybIVcRaYDW71x_3jQ_kYg46ur2irlRmEwbfhJOZXn99MES3lEv1yEMVsC0T-xa7X49K__52ffgGsN6hS7tZnchEt2fgu23zf_1W_Dt_06c12si1PLpTas0PNMpHatf37_wZv7ghdAVqKY0bUibQtdrgvSyywtsq8kVad_nVmxOR8uaDJdlgxpqVuhxYpj74y-XCwa3ijqraK3vQPH_b2jNwduU5nBnYWRF7jKl0YrGSepb_3Qejozxk8jaVUQebHWMsu6BIyMVQQoqM3IMJexl5OsDpmj7C505sXc7oDQKs1znVMkzuCCFked-l1rAor7okQH2oEXlXZwUbNvoF5-5mS0JMIPw318e9Q7CCfj1zh24OlGfUguwkOj57YoVxTdeHFFZSb_JhNwcKdk4MC9WvftG_0gjJUKuw48r42hbWFu7t5ssovF8hOWJRLWIkjtwMcL5OpwChsOpxM8LXFlcXFucxYJjeZM8Icm0wZ5NsU0MRlGQWYTGgzG5w68rMyr7XsTxbFdYWVXONrrHVZ39_9F-Alsj3p9HBwO3z2Aq35V9oMTHR9CZ70s7SO4Ys7Ws9XyceNlvwBeETB- |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Glucose+tolerance+and+beta%E2%80%90cell+function+in+islet+autoantibody%E2%80%90positive+children+recruited+to+a+secondary+prevention+study&rft.jtitle=Pediatric+diabetes&rft.au=Andersson%2C+Cecilia&rft.au=Carlsson%2C+Annelie&rft.au=Cilio%2C+Corrado&rft.au=Cedervall%2C+Elisabeth&rft.date=2013-08-01&rft.pub=John+Wiley+%26+Sons+A%2FS&rft.issn=1399-543X&rft.eissn=1399-5448&rft.volume=14&rft.issue=5&rft.spage=341&rft.epage=349&rft_id=info:doi/10.1111%2Fpedi.12023&rft.externalDBID=10.1111%252Fpedi.12023&rft.externalDocID=PEDI12023 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1399-543X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1399-543X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1399-543X&client=summon |